BMAC Stem Cell Therapy:
Why Is Everyone Talking About It?
💬 "I've heard BMAC can affect the immune system — could it help with autoimmune conditions?"
💬 "Is stem cell therapy an option for menopause symptoms? How does it actually work?"
💬 "They take bone marrow and inject it systemically? Is that really safe?"
Questions like these are becoming increasingly common in the world of regenerative medicine. BMAC (Bone Marrow Aspirate Concentrate) has long been recognized for its role in joint therapy — but interest in its broader applications for systemic immune regulation is growing rapidly.
In this post, I'll walk through the components of BMAC, how it works in the body, and what the science says about its potential connection to autoimmune conditions and menopause.
Dr. Jju — Regenerative Medicine Specialist
A specialist in regenerative medicine dedicated to finding science-backed solutions for difficult-to-treat conditions.
With 15 years of experience as a board-certified emergency medicine physician, Dr. Jju now serves as Principal Investigator at a Ministry of Health & Welfare-designated Advanced Regenerative Medicine Institution in Korea.
- Anti-aging & Aesthetics: Stem cell rejuvenation, hair loss treatment, skin boosters, fat grafting
- Joint Regeneration: PRP · BMAC · SVF for knee osteoarthritis
- Refractory Disease Research: Mechanism-focused studies using advanced regenerative technologies
Section 1. What Is BMAC? — The Regenerative Signals Hidden in Bone Marrow
BMAC is an autologous biological preparation derived from a patient's own bone marrow — typically aspirated from the iliac crest — and concentrated via centrifugation to enrich cells and growth factors. It is frequently compared to PRP (Platelet-Rich Plasma), but the two differ significantly in composition.
| Component | Primary Role | Compared to PRP |
|---|---|---|
| Mesenchymal Stem Cells (MSCs) | Tissue regeneration, immune modulation, anti-inflammation | Present in BMAC only |
| Hematopoietic Stem Cells (HSCs) | Origin of blood and immune cells | Present in trace amounts in PRP; far more concentrated in BMAC |
| TGF-β · PDGF · VEGF | Tissue repair, angiogenesis | Present in both |
| IL-1RA | Blocks IL-1 inflammatory signaling | Higher concentration in BMAC |
| BMP-2, BMP-7 | Bone and cartilage regeneration signals | Present in BMAC only |
| IGF-1 · FGF | Cell proliferation, anti-aging | Present in both |
— Lim et al., Bone Marrow Aspirate Concentrate: Its Uses in Osteoarthritis, PMC 7247342, 2020
Of particular clinical interest is IL-1RA (Interleukin-1 Receptor Antagonist) — a key molecule that blocks IL-1-mediated inflammatory cascades in both joints and systemic tissues. BMAC contains IL-1RA at notably high concentrations, which is one reason it has attracted attention beyond musculoskeletal applications.
Curious about the different types of stem cells and how they work? 👉 Check out this post for a breakdown of stem cell types and mechanisms.
Section 2. From Joints to the Whole Body — Expanding the Reach of BMAC
BMAC already has a substantial and growing body of clinical evidence in musculoskeletal applications — including knee and hip osteoarthritis, cartilage damage, and ligament injuries. A 2024 systematic review encompassing 876 patients consistently reported reductions in pain, improvements in function, and better quality of life. Several studies also show BMAC outperforming PRP and hyaluronic acid in mid-term durability. This well-established track record in local orthopedic use has laid the credibility foundation for exploring broader systemic applications.
Building on that foundation, there is growing clinical interest in administering BMAC systemically for purposes of anti-aging and immune regulation. Unlike targeted joint injections, systemic delivery allows the cells, growth factors, and cytokines within the concentrate to circulate through the bloodstream — engaging the following mechanisms:
Immune Remodeling
MSCs suppress overactivated inflammatory cytokines such as TNF-α and IL-1β, while activating regulatory T cells (Tregs).
Reduction of Chronic Low-Grade Inflammation
Bone marrow-derived components may attenuate "inflammaging" — the chronic systemic inflammation that accumulates with age.
Stem Cell Homing
Circulating stem cells migrate to sites of inflammation or injury, activating local repair signals in damaged tissues.
Paracrine Signaling
Even without direct differentiation, stem cells release exosomes and growth factors that stimulate regeneration in surrounding tissue.
One clinical study frequently cited in support of systemic bone marrow-derived MSC delivery is the CRATUS trial (Golpanian et al., 2017). In this Phase I study, 15 elderly patients with aging frailty received intravenous infusions of bone marrow-derived MSCs. No serious adverse events were observed, and significant improvements were seen in 6-minute walk distance, physical function, and TNF-α levels at 6 months.
— Golpanian et al., Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty, PMC 5861970, 2017
The CRATUS trial used allogeneic MSCs — cells harvested from a donor's bone marrow and then laboratory-expanded to hundreds of millions of cells. BMAC systemic therapy is fundamentally different: it uses the patient's own bone marrow, aspirated and concentrated on the same day, without any culture expansion.
Cell count, purity, and dosage are not directly comparable, and no large-scale RCT has yet validated systemic BMAC delivery as a standalone protocol. Citing CRATUS figures as direct evidence for BMAC efficacy would therefore be scientifically inaccurate. That said, the study does serve as a meaningful mechanistic reference for the immune-modulatory potential of bone marrow-derived components delivered systemically.
Section 3. Why Autoimmune Conditions & Menopause Are in Focus — A Mechanism-Based Perspective
① Autoimmune Conditions (e.g., Psoriasis) — Can BMAC Quiet an Overactive Immune System?
Psoriasis is an autoimmune condition in which immune cells — primarily Th17 and Th1 — attack the body's own skin cells. Biologic drugs work by blocking TNF-α, IL-17, or IL-23. Notably, the MSCs and IL-1RA found in BMAC engage overlapping anti-inflammatory pathways.
| Autoimmune Pathway | How BMAC May Intervene |
|---|---|
| TNF-α overactivation | MSC paracrine signaling suppresses TNF-α secretion |
| IL-1β-mediated inflammation | IL-1RA competitively blocks IL-1 receptor binding |
| T cell hyperreactivity | MSCs induce regulatory T cells (Tregs), promoting immune tolerance |
| M1 macrophage polarization | MSCs shift macrophage differentiation toward anti-inflammatory M2 phenotype |
Large-scale randomized trial data for BMAC in psoriasis specifically are still limited. However, the mechanistic pathways through which immune overactivation could be dampened are well-defined, and positive clinical observations have been reported in practice settings.
② Menopause — The Link Between Bone Marrow Stem Cells and Ovarian Function
Menopause is more than a simple decline in estrogen. It is a complex aging process involving follicular depletion, shifts in systemic immune tone, rising chronic inflammation, and a decline in bone marrow stem cell activity — all occurring in parallel.
Additionally, a foundational study published in Scientific Reports (2015) demonstrated that bone marrow-derived MSCs can directly secrete estrogen via the aromatase (CYP450) pathway.
— Frontiers in Immunology, Bone Marrow Mesenchymal Stem Cells in Premature Ovarian Failure, PMC 9646528, 2022
Here's why BMAC is drawing particular interest in the context of menopause management:
Indirect Hormonal Environment Support
Potential to stimulate biological signaling pathways involved in restoring estrogen-producing microenvironments
Non-Hormonal Alternative to HRT
A regenerative, hormone-free approach for those who cannot or choose not to pursue hormone replacement therapy
Systemic Inflammation Control
Addressing the inflammaging that worsens with menopause — potentially easing fatigue, joint discomfort, and skin changes
Autologous — No Rejection Risk
Derived from the patient's own body, eliminating concerns about immune rejection or disease transmission
③ Direct Skin Injection — A New Approach for Menopausal Flushing & Rosacea
Beyond systemic administration, BMAC is also being explored as a direct intradermal injection in clinical settings. Of particular note are cases of persistent menopausal hot flushes and rosacea — conditions that often become refractory and difficult to manage after menopause — where improvement has been observed following localized BMAC treatment.
The rationale is as follows: after menopause, vascular instability and neurogenic inflammation in the skin tend to worsen. The MSCs and growth factors (VEGF, TGF-β) within BMAC may help recalibrate cutaneous vascular signaling and dampen immune cell hyperreactivity. The Th1/Th17 immune axis — a key driver of rosacea pathophysiology — is also among the targets of MSC-mediated immune modulation, providing further theoretical grounding.
📋 Key Takeaways
- BMAC is an autologous biologic concentrate containing MSCs, TGF-β, IL-1RA, and a rich array of regenerative components — with a well-established clinical track record in musculoskeletal applications.
- Systemic delivery enables immune remodeling, anti-inflammatory effects, and paracrine signaling that extend beyond joint tissue.
- In autoimmune conditions such as psoriasis, BMAC engages pathways — including TNF-α suppression, IL-1 blockade, and Treg induction — that overlap with those targeted by biologic drugs.
- Clinical data on bone marrow-derived MSCs suggest potential for estrogen environment restoration and menopausal symptom relief; intradermal application has also shown promise for hot flushes and rosacea.
- BMAC systemic therapy is fundamentally distinct from the cultured allogeneic MSC infusions studied in trials like CRATUS — cell counts, preparation methods, and delivery protocols are not directly comparable.
- As an autologous therapy, rejection risk is absent and short-term safety appears favorable — but large-scale RCT data remain limited, and suitability should be assessed on an individual basis by a qualified specialist.
Regenerative medicine is evolving at a remarkable pace. In areas where clinical practice is moving ahead of large-scale trial data — as is the case with systemic BMAC therapy — a deep understanding of the underlying mechanisms and careful clinical judgment matter most. If you have questions or are considering this approach, a consultation with a specialist is always the right first step.
📌 Learn More About Dr. Joo & Saeron Clinic
If you'd like to explore further or get in touch, visit the links below.
The information provided in this blog is for educational and informational purposes only. Individual treatment decisions should always be made in consultation with a qualified medical professional.